Overview

MK0767 in Type 2 Diabetes (0767-012)

Status:
Terminated
Trial end date:
2003-11-01
Target enrollment:
Participant gender:
Summary
This is a clinical trial in patients with Type 2 Diabetes to test the safety of MK0767. This study will also see how effective MK0767 is in lowering markers of glucose metabolism and improving the lipid profile and non-HDL cholesterol when compared with placebo and pioglitazone.
Phase:
Phase 2
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.